This opportunity is no longer accepting applications.
grant PAR-22-111

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)

This grant aims to support research that strengthens the basis for future therapies in areas related to diabetes, obesity, endocrinology, metabolism, digestive and liver diseases, nutrition, kidney and urological diseases, and blood disorders. It encourages applicants to align their work with the research priorities of the National Institute of Diabetes and Digestive and Kidney Diseases and to…

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseas…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute of Diabetes and Digestive and Kidney Diseases
Program: SBIR

Dates

Opportunity Released: February 4, 2022
Open for Submission: February 4, 2022
Submission Deadline: January 7, 2025
Application Window Closes: January 7, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.